BioSpace News Archive

Fulcrum Therapeutics, Inc. today announced positive interim results from the ongoing single- and multiple-ascending dose (SAD and MAD) Phase 1 trial with FTX-6058 in healthy adult volunteers.

According to the report, the global heat therapy market was valued at US$ 1.1 Bn in 2020. It is projected to expand at a CAGR of ~4% from 2021 to 2031.

According to the report, the global acne scar treatment market was valued at US$ 6 Bn in 2020 and is projected to expand at a moderate CAGR from 2021 to 2031.

Thanks to the increasing prevalence of target infectious of diseases, the global market for clinic laboratory services is experiencing high growth in its valuation.

Sparx Therapeutics, an emerging biopharmaceutical company specializing in developing multi-specific antibody and antibody-drug conjugate drugs, announced the appointment of Ms. Juxiang Xia, a former Fosun veteran, as the COO of Sparx Yangzhou.

Nautilus Biotechnology, Inc., a life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome, reported financial results for the second quarter ended June 30, 2021.

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal platform delivery technology, reported financial results for the second quarter ended June 30, 2021, along with a corporate update.

TYME Technologies, Inc., an emerging biotechnology company developing cancer metabolism-based therapies, announced financial and operating results for its fiscal first quarter ended June 30, 2021.

EyeGate Pharmaceuticals, Inc. announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale, in a registered direct offering priced at-the-marked under Nasdaq rules, of 4,668,844 shares of its common stock at a purchase price of $2.3025 per share for gross proceeds of approximately $10.75 million, before deducting placement agent’s fees and other offering expenses.

NRx Pharmaceuticals, a clinical stage, global biopharmaceutical company announced that the NRx Team, together with Prof Jonathan Javitt, Founder, Chairman and CEO of NRx, will ring the Nasdaq Closing Bell on Tuesday, August 10, 2021 in celebration of NRx’s listing on the Nasdaq Exchange.